ATCC ATCC Logo 0

Cell Lines for Enhanced Virus Production

Need high-titer viral stocks for vaccine or gene therapy development? Explore our resources below to discover how STAT1 and BAX knockout cell lines can help.

Vaccine Development Resources

ATCC is committed to providing researchers with the virus-producing cell lines, pathogenic microbial strains, and purified pneumococcal polysaccharides needed to support vaccine research and development.

Accelerate your vaccine and gene therapeutic development projects

The continual spread of deadly viruses necessitates the development of novel prevention and treatment options; however, the development of a new antiviral vaccine can be challenged by low-yielding manufacturing processes. Similarly, the development of gene therapies is constrained during the large-scale production of adeno-associated virus (AAV) delivery platforms for gene transfer.

To speed the pace of these various areas of bioproduction, ATCC addressed the need for efficient viral replication by optimizing three cell lines commonly used in virus manufacturing. Here, we used CRISPR/Cas9 gene-editing technology to develop STAT1 and BAX knockout cell lines capable of producing high-titer viral stocks. These newly created cell lines can produce model clinical viruses and adeno-associated viruses at titers much higher than the parental cell lines, providing an efficient method for biopharmaceutical companies to increase production while reducing associated costs.  Discover how these advanced biological models can be used in your vaccine and gene therapeutic development projects.

Explore our related resources

Vaccine Development

ATCC provides the virus-producing cell lines, microbial strains, and pneumococcal polysaccharides needed for vaccine research and development.

Explore resources for vaccine development

Custom Solutions

Can't find exactly what you need? Ask ATCC to make it for you! We will tailor our custom services to meet your specific needs.

Customize your research

Reduce the costs associated with generating viral vaccines and gene therapies

ATCC’s cell lines for enhanced viral production have broad applicability for bioproduction in basic research and the pharmaceutical industry. Because of their ability to yield higher virus titers than their wild-type counterparts, these enhanced virus-producing cell lines have the potential to significantly reduce the costs associated with generating viral vaccines and gene therapies.

  • 2 cell lines optimized for vaccine manufacturing
  • 1 cell line optimized for gene therapy delivery
  • Superior clinical virus or AAV yields compared to parental lines
  • 10 to 30-fold higher virus yields possible
  • Broad applicability for basic research or industrial scale manufacturing
  • Gene-edited for precise and stable STAT1 and STAT1/BAX knockouts
  • Similar growth profiles to the parental cell lines
  • Scalable for large- to small-scale production
  • cGMP-compliant custom services available
  • ATCC quality and performance

 

Graphs showing ATCC CRISPR-edited virus-producing cell lines show superior virus yields compared to parental cell lines.

Figure 1: ATCC CRISPR-edited virus-producing cell lines show superior virus yields compared to parental cell lines. Staining of TCID50 of viral supernatants from MDCK.STAT1 KO, Vero.STAT1 KO, and 293.STAT1 BAX KO show a 10-fold increase in Influenza A virus production, Dengue virus type II production, and Sendai virus production over their respective parental cell lines



Graphs showing ATCC CRISPR-edited virus-producing cell lines show increase virus genome copy number compared to parental cell lines

Figure 2: ATCC CRISPR-edited virus-producing cell lines show increase virus genome copy number compared to parental cell lines. Staining of TCID50 of viral supernatants from MDCK.STAT1KO, Vero.STAT1KO, and 293.STAT1 BAX KO show a 2-fold increase in Influenza A virus production, a 30-fold increase in Dengue virus type II production, and a 1.8-fold increase Sendai virus production over their respective parental cell lines.

Watch our webinar to learn how to amplify your viral vaccine production